Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¿¹Ãø - Áö¿ªº° ºÐ¼® : Àå±â À¯Çüº°, ¿ëµµº°, °ø±Þ¿øº°, À¯Çüº°(-2030³â)
South & Central America Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type, Application, Source, and Type
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº 2022³â 1¾ï 3,238¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 6¾ï 5,425¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 22.1%·Î ÃßÁ¤µË´Ï´Ù.
â¾à Ȱµ¿¿¡ ´ëÇÑ ÁÖ·ÂÀÌ Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀ» µÞ¹Þħ
½Å¾à ¹× ÷´Ü¾à¿¡ ´ëÇÑ ¼ö¿äÀÇ °íÁ¶°¡, â¾à ¹× ¿¬±¸ ÀüüÀÇ ÆäÀ̽º¸¦ ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ClinicalTrials.gov¿¡ µû¸£¸é 2020³â ÃÑ ÀÓ»ó½ÃÇè ¼ö´Â 356,282°ÇÀ¸·Î ÃßÁ¤µË´Ï´Ù. Hubrecht ¿¬±¸¼ÒÀÇ ÃÖ±Ù Á¶»ç¿¡ µû¸£¸é, ¿À°¡³ëÀ̵å´Â ±× ¾à¹°ÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ¾ø´Â ȯÀÚ¸¦ È®ÀÎÇÔÀ¸·Î½á °ªºñ½Ñ ¾à¹°ÀÇ ºñ¿ë È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¼¼°èÀÇ ÀÓ»ó½ÃÇè Áõ°¡´Â ¿À°¡³ëÀÌµå ¸ðµ¨À» Æ÷ÇÔÇÑ Ã·´Ü ÀÇ·á±â¼ú ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡, â¾à¿¡ ÀÖ¾î¼ÀÇ ¿À°¡³ëÀ̵å´Â ¾Ï¿¡¸¸ ÇÑÁ¤µÇÁö ¾Ê°í, ³¶Æ÷¼º ¼¶À¯Áõ, ´Ù¹ß¼º ³¶Æ÷½Å, ¼ÒµÎÁõ, ÀåÀ̳ª ±âµµÀÇ °¨¿°Áõ µî, ´Ù¸¥ Áúȯ¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿À°¡³ëÀ̵å´Â ±â°üÀÇ ±¸Á¶ ¹× ±â´É°ú °°Àº ±â°üÀÇ Æ¯¼ºÀ» ¿ä¾àÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿À°¡³ëÀ̵å´Â Á¶Á÷À̳ª Àå±âÀÇ º»·¡ÀÇ À¯ÀüÀû ¹× ÈļºÀû »óŸ¦ º¹¿øÇÒ ¼ö Àֱ⠶§¹®¿¡ À¯ÀüÀÚ ÆíÁý¿¡ ÀûÇÕÇÕ´Ï´Ù. ´Ù¾çÇÑ ¿¬±¸´Â CRISPR-Cas9 ±â¼ú°ú ¿À°¡³ëÀ̵åÀÇ Á¶ÇÕ¿¡ ÀÇÇÑ ÁÁÀº °á°ú¸¦ º¸¿©ÁÖ¸ç, ³¶Æ÷¼º ¼¶À¯Áõ¿¡¼ ȹ±âÀûÀÎ ±âȸ¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. 2020³â¿¡ ¹ßÇ¥µÈ ¿¬±¸ 'CRISPR-Based Adenine Editors Correct Nonsense Mutation in a Cystic Fibrosis Organoid Biobank'¿¡ µû¸£¸é, ³¶Æ÷¼º ¼¶À¯Áõ Àå°ü ¿À°¡³ëÀ̵åÀÇ ¹ÙÀÌ¿À¹ðÅ©´Â 664¸íÀÇ È¯ÀÚ¸¦ ´ëÇ¥Çϰí, ±× Áß 20%±îÁö ¾Æµ¥´Ñ ¿°±â ÆíÁý±â´Â ³¶Æ÷¼º ¼¶À¯Áõ ¸· °üÅë ÀüµµÃ¼ ¼ö¿ëüÀÇ ³¼¾½º µ¹¿¬º¯À̸¦ ÀÌ·ÐÀûÀ¸·Î È¿À²ÀûÀ¸·Î º¹±¸ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. ÀϺΠµ¿¹° ¸ðµ¨¿¡¼ À¯ÀüÀÚ ÆíÁý ¿À°¡³ëÀ̵åÀÇ ¼º°ú´Â ÀÖÁö¸¸, ±× È¿À²Àº ÇöÀúÈ÷ ³·°í ¼º°ø·üÀº ³ôÁö ¾Ê½À´Ï´Ù. ±×·¯¹Ç·Î À¯ÀüÀÚ ÆíÁý ¿À°¡³ëÀ̵åÀÇ ¾ÈÀü¼º, Àå±â ¾ÈÁ¤¼º ¹× ±â´É¼ºÀ» À§ÇÑ °úÁ¤ÀÇ ¿¬±¸ °³¹ßÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
¶ÇÇÑ COVID-19ÀÇ À¯ÇàÀº Àΰ£ÀÇ Æó À¯±âü ¸ðµ¨À» °³¹ßÇÒ Çʿ伺À» ÀÏÀ¸Ä×½À´Ï´Ù. ¿¹¸¦ µé¾î, Millipore Sigma´Â 3dGRO Àΰ£ Æó ¿À°¡³ëÀÌµå ¹è¾ç ½Ã½ºÅÛÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¿¬±¸ÀÚ°¡ Àΰ£ Æó »óÇÇÀÇ ¿À°¡³ëÀÌµå ¸ðµ¨À» ¹è¾çÇϱâ À§ÇÑ Àå±â Á¶Á÷À» Á¦¾îÇϰí, Á¢±ÙÇϰí, ÀçÇöÇÒ ¼ö ÀÖ°Ô Çϰí, ¿¬±¸ Áß¿¡ ±àÁ¤ÀûÀÌ°í ¼º°øÀûÀÎ °á°ú¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ Çõ½ÅÀº ½ÃÀå ¼ºÀå¿¡ ´õ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå °³¿ä
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ¾Ï ȯÀÚ Áõ°¡, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ¿À°¡³ëÀ̵åÀÇ ¿¬±¸°³¹ß Áõ°¡¿¡ ÀÇÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)(-2030³â)
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¼¼ºÐÈ
Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº Àå±â À¯Çüº°, ¿ëµµº°, °ø±Þ¿øº°, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.
Àå±â À¯Çü¿¡ µû¶ó Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº Àå, °£, À§, ÃéÀå, Æó, ³ú, ½ÅÀå µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Àå ºÎ¹®Àº 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
À¯Çüº°·Î º¸¸é Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ±â±¸, ¼Ò¸ðǰ, ¼ºñ½º·Î ±¸ºÐµË´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®Àº 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¿ëµµº°·Î´Â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ¹ß»ý »ý¹°ÇÐ Áúȯ, °¨¿°Áõ º´¸®ÇÐ, Àç»ý ÀÇ·á, ¾à¹° µ¶¼º ¹× À¯È¿¼º ½ÃÇè, â¾à ¹× ¸ÂÃãÇü ÀÇ·á, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼´Â ¹ß»ý »ý¹°ÇÐ Áúȯ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Ãâó¸¦ ±â¹ÝÀ¸·Î Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ´Ù´É¼º Áٱ⠼¼Æ÷¿Í Àå±â ƯÀÌÀûÀÎ ¼ºÃ¼ Áٱ⠼¼Æ÷·Î À̺е˴ϴÙ. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼´Â ´Ù´É¼º Áٱ⼼Æ÷ ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
±¹°¡º°·Î º¸¸é Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁúÀÌ µ¶Á¡Çß½À´Ï´Ù.
Cellsce, InSphero, Merck KGaA, STEMCELL Technologies Inc, Thermo Fisher Scientific Inc´Â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
- Áß³²¹Ì ÁÖ¿ä ÀλçÀÌÆ®
- Áß³²¹Ì ½ÃÀåÀÇ ¸Å·Â
Á¦3Àå Á¶»ç ¹æ¹ý
- Á¶»ç ¹üÀ§
- 2Â÷ Á¶»ç
- 1Â÷ Á¶»ç
Á¦4Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå »óȲ
Á¦5Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ
- ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- Á¾¾ç ¸ðµ¨¸µ ¹× ¹ÙÀÌ¿À¹ðÅ© ¼ö¿ä Áõ°¡
- °³º°È ÀǾàǰÀÇ Ã¤¿ë È®´ë
- µ¿¹° ½ÇÇè ¸ðµ¨ÀÇ ´ëüǰ °³¹ß¿¡ ÁÖ¸ñÀÇ °íÁ¶
- ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âÁ¸ ¿öÅ©Ç÷ο쿡 ¿À°¡³ëÀ̵åÀÇ ÅëÇÕ¿¡ °üÇÑ ¹®Á¦
- ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·
- ÁÖ¿ä ½ÃÀå ±âȸ
- ÇâÈÄ µ¿Çâ
- ¿À°¡³ëÀÌµå ¹× Organ-On-A-ChipÀÇ Á¶ÇÕ
- ¿µÇ⠺м®
Á¦6Àå ¿À°¡³ëÀÌµå ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¼öÀÍ(2022-2030³â)
Á¦7Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : Àå±â À¯Çüº°(-2030³â)
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : Àå±â À¯Çüº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
- ˤ
- Àå
- °£
- ̎ˌ
- Æó
- ³ú
- ½ÅÀå
- ±âŸ
Á¦8Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : ¿ëµµº°(-2030³â)
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : ¿ëµµº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
- ¹ß»ý »ý¹°ÇÐ
- °¨¿°Áõ º´ÅÂÇÐ
- Àç»ý ÀÇ·á
- ¾à¹° µ¶¼º ¹× È¿´É ½ÃÇè
- â¾à ¹× ¸ÂÃãÇü ÀÇ·á
- ±âŸ
Á¦9Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : °ø±Þ¿øº°(-2030³â)
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : °ø±Þ¿øº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
- ´Ù´É¼º Áٱ⼼Æ÷
- Àå±â ƯÀÌÀû ¼ºÃ¼ Áٱ⠼¼Æ÷
Á¦10Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : À¯Çüº°(-2030³â)
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : À¯Çüº° ¼öÀÍ Á¡À¯À²(%)(2022³â, 2030³â)
- ±â±â
- ¼Ò¸ðǰ
- ¼ºñ½º
Á¦11Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : ±¹°¡º° ºÐ¼®
- Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ Áß³²¹Ì
Á¦12Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ
Á¦13Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¾÷°è Á¤¼¼
- ½ÃÀå ÁøÃâ±â¾÷ÀÇ ¼ºÀå Àü·«(%)
- À¯±â°³¹ß
- ¹«±â°³¹ß
Á¦14Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
- STEMCELL Technologies Inc.
- Cellesce Ltd
- Thermo Fisher Scientific Inc
- Merck KGaA
- InSphero
Á¦15Àå ºÎ·Ï
AJY
The South & Central America organoids market is expected to grow from US$ 132.38 million in 2022 to US$ 654.25 million by 2030. It is estimated to grow at a CAGR of 22.1% from 2022 to 2030.
Focus on Drug Discovery Activities Fuel South & Central America Organoids Market
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.
Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study 'CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,' published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.
Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.
South & Central America Organoids Market Overview
The South & Central America organoids market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for organoids.
South & Central America Organoids Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Organoids Market Segmentation
The South & Central America organoids market is segmented into organ type, type, application, Source, and country.
Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the South & Central America organoids market in 2022.
Based on type, the South & Central America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.
Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the South & Central America organoids market in 2022.
Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held the larger share of the South & Central America organoids market in 2022.
Based on country, the South & Central America organoids market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America organoids market in 2022.
Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, are some of the leading companies operating in the South & Central America organoids market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South America organoids market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the South America organoids market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth South America market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 South & Central America Key Insights
- 2.2 South & Central America Market Attractiveness
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. South & Central America Organoids Market Landscape
- 4.1 Overview
- 4.2 South & Central America PEST Analysis
5. South & Central America Organoids Market - Key Industry Dynamics
- 5.1 Key Market Drivers:
- 5.1.1 Increasing Demand for Tumor Modeling and Biobanking
- 5.1.2 Growing Adoption of Personalized Drugs
- 5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
- 5.2 Key Market Restraints:
- 5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
- 5.2.2 Dearth of Skilled Professionals
- 5.3 Key Market Opportunities:
- 5.3.1 Focus on Drug Discovery Activities
- 5.4 Future Trends:
- 5.4.1 Combining Organoid with Organ-On-A-Chip
- 5.5 Impact Analysis:
6. Organoids Market - South & Central America Market Analysis
- 6.1 South & Central America Organoids Market Revenue (US$ Mn), 2022 - 2030
7. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Organ Type.
- 7.1 Overview
- 7.2 South & Central America Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
- 7.3 Stomach
- 7.3.1 Overview
- 7.3.2 Stomach: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Intestine
- 7.4.1 Overview
- 7.4.2 Intestine: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Liver
- 7.5.1 Overview
- 7.5.2 Liver: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6 Pancreas
- 7.6.1 Overview
- 7.6.2 Pancreas: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.7 Lung
- 7.7.1 Overview
- 7.7.2 Lung: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.8 Brain
- 7.8.1 Overview
- 7.8.2 Brain: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.9 Kidney
- 7.9.1 Overview
- 7.9.2 Kidney: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Application.
- 8.1 Overview
- 8.2 South & Central America Organoids Market Revenue Share, by Application 2022 & 2030 (%)
- 8.3 Developmental Biology
- 8.3.1 Overview
- 8.3.2 Developmental Biology: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Disease Pathology of Infectious Disease
- 8.4.1 Overview
- 8.4.2 Disease Pathology of Infectious Disease: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Regenerative Medicine
- 8.5.1 Overview
- 8.5.2 Regenerative Medicine: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 8.6 Drug Toxicity and Efficacy Testing
- 8.6.1 Overview
- 8.6.2 Drug Toxicity and Efficacy Testing: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 8.7 Drug Discovery and Personalized Medicine
- 8.7.1 Overview
- 8.7.2 Drug Discovery and Personalized Medicine: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Source.
- 9.1 Overview
- 9.2 South & Central America Organoids Market Revenue Share, by Source 2022 & 2030 (%)
- 9.3 Pluripotent Stem Cells
- 9.3.1 Overview
- 9.3.2 Pluripotent Stem Cells: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4 Organ-specific Adult Stem Cells
- 9.4.1 Overview
- 9.4.2 Organ-specific Adult Stem Cells: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Type
- 10.1 Overview
- 10.2 South & Central America Organoids Market Revenue Share, by Type 2022 & 2030 (%)
- 10.3 Instruments
- 10.3.1 Overview
- 10.3.2 Instruments: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 10.4 Consumables
- 10.4.1 Overview
- 10.4.2 Consumables: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
- 10.5 Services
- 10.5.1 Overview
- 10.5.2 Services: South & Central America Organoids Market - Revenue and Forecast to 2030 (US$ Million)
11. South & Central America Organoids Market - Country Analysis
- 11.1 South & Central America Organoids Market: Overview
- 11.1.1 South & Central America Organoids Market by Country
- 11.1.1.1 Brazil
- 11.1.1.1.1 Overview
- 11.1.1.1.2 Brazil Organoids Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.1.3 Brazil Organoids Market, by Organ Type
- 11.1.1.1.4 Brazil Organoids Market, by Application
- 11.1.1.1.5 Brazil Organoids Market, by Source
- 11.1.1.1.6 Brazil Organoids Market, by Type
- 11.1.1.2 Argentina
- 11.1.1.2.1 Overview
- 11.1.1.2.2 Argentina Organoids Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.2.3 Argentina Organoids Market, by Organ Type
- 11.1.1.2.4 Argentina Organoids Market, by Application
- 11.1.1.2.5 Argentina Organoids Market, by Source
- 11.1.1.2.6 Argentina Organoids Market, by Type
- 11.1.1.3 Rest of South & Central America
- 11.1.1.3.1 Overview
- 11.1.1.3.2 Rest of South & Central America Organoids Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.1.3.3 Rest of South & Central America Organoids Market, by Organ Type
- 11.1.1.3.4 Rest of South & Central America Organoids Market, by Application
- 11.1.1.3.5 Rest of South & Central America Organoids Market, by Source
- 11.1.1.3.6 Rest of South & Central America Organoids Market, by Type
12. Pre & Post COVID-19 Impact
- 12.1 Pre & Post COVID-19 Impact
13. South & Central America Organoids Market Industry Landscape
- 13.1 Overview
- 13.2 Growth Strategies Done by the Companies in the Market, (%)
- 13.3 Organic Developments
- 13.4 Inorganic Developments
14. South & Central America Organoids Market, Key Company Profiles
- 14.1 STEMCELL Technologies Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Cellesce Ltd
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Thermo Fisher Scientific Inc
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 Merck KGaA
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 InSphero
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
15. Appendix
- 15.1 About Us
- 15.2 Glossary of Terms